Showing 1291-1300 of 23044 results for "".
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Menin Inhibitors: Biologic and Clinical Rationale
https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Expert Recommendations and Key Takeaways
https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Treatment of a Broader Population of Patients With DMD
https://reachmd.com/programs/cme/treatment-of-a-broader-population-of-patients-with-dmd/33167/By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their abilitExpert Consensus Addresses Complication Management in Ablative Facial Resurfacing
https://reachmd.com/programs/modern-aesthetics/expert-consensus-addresses-complication-management-in-ablative-facial-resurfacing/56629/High-impact resurfacing demands high-level complication management